<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813044</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-0344</org_study_id>
    <nct_id>NCT02813044</nct_id>
  </id_info>
  <brief_title>Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A number of studies have compared the effects of total intravenous anesthesia(TIVA) versus&#xD;
      inhalational anesthesia on perioperative period during transsphenoidal surgery. However, they&#xD;
      have limitations especially for the phase of recovery after anesthesia: a fragmentary&#xD;
      assessment. Quality of Recovery 40 (QoR-40) questionnaire was multi-dimensionally designed to&#xD;
      assess the degree of recovery, specially after anesthesia and surgery. In this study, the&#xD;
      investigators aim to compare the quality of recovery after inhalational anesthesia and after&#xD;
      TIVA through QoR-40 questionnaire in patients undergoing transsphenoidal surgery for&#xD;
      pituitary tumor under general anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2016</start_date>
  <completion_date type="Actual">June 15, 2018</completion_date>
  <primary_completion_date type="Actual">June 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QoR-40 score</measure>
    <time_frame>1 day</time_frame>
    <description>We compare the QoR-40 scores of two groups 1 day after the operation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Pituitary Tumor</condition>
  <arm_group>
    <arm_group_label>TIVA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anesthesia is maintained with propofol during surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inhalation anesthesia group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anesthesia is maintained with sevoflurane during surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>total intravenous anesthesia (TIVA)</intervention_name>
    <description>In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.</description>
    <arm_group_label>TIVA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhalation anesthesia group</intervention_name>
    <description>In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.</description>
    <arm_group_label>inhalation anesthesia group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over age 19&#xD;
&#xD;
          -  Scheduled to undergo transsphenoidal surgery for pituitary tumor&#xD;
&#xD;
          -  ASA class I and II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 55%&#xD;
&#xD;
          -  Third-degree atrioventricular block&#xD;
&#xD;
          -  Second-degree atrioventricular block (P:QRS ratio of 3:1 or higher)&#xD;
&#xD;
          -  Fever&#xD;
&#xD;
          -  History of myocardial infarction, stroke or cardiac surgery within the previous 1 year&#xD;
&#xD;
          -  Severe neurological disease&#xD;
&#xD;
          -  Use of sedative, opioid or sleep-inducing drugs&#xD;
&#xD;
          -  Allergic history of any study drug&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Associate Professor Department of Anesthesiology and Pain Medicine,</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Al-Shaikh B, George William M, Van Zundert AA. Using atmospheric pressure to inflate the cuff of the Portex Laryngeal Mask. Anaesthesia. 2005 Mar;60(3):296-7.</citation>
    <PMID>15710025</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anesthesia</keyword>
  <keyword>intravenous</keyword>
  <keyword>neurosurgery</keyword>
  <keyword>pituitary neoplasm</keyword>
  <keyword>postoperative period</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

